课题基金 / 基金详情

Predicting therapy resistance in castration-resistant prostate cancer with circulating tumor DNA

Predicting therapy resistance in castration-resistant prostate cancer with circulating tumor DNA
利用循环肿瘤 DNA 预测去势抵抗性前列腺癌的治疗抵抗力
批准号:
371318
负责人:
Wyatt Alexander W
金额:
$37.62万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-09-01 至 2020-09-01

项目摘要

项目成果

Wyatt Alexander W的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The standard of care therapies for advanced prostate cancer, abiraterone and enzalutamide, are not effective in 20-40% of patients. We currently are unable to recognize this subset of patients up-front, which means they are inevitably treated with a drug
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
  • 批准号:
    451909
  • 项目类别:
    Operating Grants
  • 资助金额:
    $61.3万
  • 财政年份:
    2021
  • 负责人:
    Wyatt Alexander W
  • 依托单位:
Genomic dissection of de novo metastatic prostate cancer prior to treatment
  • 批准号:
    445330
  • 项目类别:
    Operating Grants
  • 资助金额:
    $53.5万
  • 财政年份:
    2021
  • 负责人:
    Wyatt Alexander W
  • 依托单位:
Circulating tumour DNA as a precision oncology tool for metastatic bladder cancer
  • 批准号:
    373906
  • 项目类别:
    Salary Programs
  • 资助金额:
    $10.56万
  • 财政年份:
    2017
  • 负责人:
    Wyatt Alexander W
  • 依托单位:
海外基金